Factors Important to the Prioritization and Development of Successful Topical Microbicides for HIV-1Report as inadecuate




Factors Important to the Prioritization and Development of Successful Topical Microbicides for HIV-1 - Download this document for free, or read online. Document in PDF available to download.

Molecular Biology InternationalVolume 2012 2012, Article ID 781305, 12 pages

Review ArticleTopical Microbicide and STI Research Department, ImQuest BioSciences, Inc., 7340 Executive Way, Suite R, Frederick, MD 21704, USA

Received 13 February 2012; Accepted 11 May 2012

Academic Editor: Gilda Tachedjian

Copyright © 2012 Karen W. Buckheit and Robert W. Buckheit. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Significant advancements in topical microbicide development have occurred since the prevention strategy was first described as a means to inhibit the sexual transmission of HIV-1. The lack of clinical efficacy of the first generation microbicide products has focused development attention on specific antiretroviral agents, and these agents have proven partially successful in human clinical trials. With greater understanding of vaginal and rectal virus infection, replication, and dissemination, better microbicide products and delivery strategies should result in products with enhanced potency. However, a variety of development gaps exist which relate to product dosing, formulation and delivery, and pharmacokinetics and pharmacodynamics which must be better understood in order to prioritize microbicide products for clinical development. In vitro, ex vivo, and in vivo models must be optimized with regard to these development gaps in order to put the right product at the right place, at the right time, and at the right concentration for effective inhibition of virus transmission. As the microbicide field continues to evolve, we must harness the knowledge gained from unsuccessful and successful clinical trials and development programs to continuously enhance our preclinical development algorithms.





Author: Karen W. Buckheit and Robert W. Buckheit Jr.

Source: https://www.hindawi.com/



DOWNLOAD PDF




Related documents